表紙
市場調查報告書

腫瘤壞死因子受體超家族成員10B:開發中產品分析

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520775
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤壞死因子受體超家族成員10B:開發中產品分析 Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 81 Pages
簡介

本報告提供以腫瘤壞死因子受體超家族成員10B為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

腫瘤壞死因子受體超家族成員10B;概要

腫瘤壞死因子受體超家族成員10B;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • 第一三共
  • F. Hoffmann-La Roche Ltd
  • Galaxy Biotech LLC
  • MedImmune LLC
  • Neonc Technologies Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2208TDB

Summary

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 5, 11, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Hematological Disorders, Immunology and Respiratory which include indications Colorectal Cancer, Solid Tumor, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastrointestinal Tract Cancer, Glioma, Hematological Tumor, Liver Cancer, Liver Cirrhosis, Liver Fibrosis, Lung Cancer, Malignant Ascites, Malignant Glioma, Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Pancreatitis, Peritoneal Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sarcomas, Systemic Sclerosis (Scleroderma), T-Cell Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Overview
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Apollo Therapeutics LLC
  • AstraZeneca Plc
  • Beijing Sinotau Pharmaceutical Technology Co Ltd
  • Beijing Sunbio Biotech Co Ltd
  • Biomirex Inc
  • Boehringer Ingelheim International GmbH
  • Chengdu Huachuang Biotechnology Co Ltd
  • Clover Biopharmaceuticals
  • D&D Pharmatech Co Ltd
  • Daiichi Sankyo Co Ltd
  • Galaxy Biotech LLC
  • Genmab A/S
  • i2 Pharmaceuticals Inc
  • IGM Biosciences Inc
  • Inhibrx Inc
  • JN Biosciences LLC
  • MacroGenics Inc
  • Neonc Technologies Inc
  • Obio Technology (Shanghai) Corp Ltd
  • Polaris Pharmaceuticals Inc
  • Shanghai Gebaide Biotechnology Co Ltd
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drug Profiles
  • ABBV-621 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AD-510 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BI-905711 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Antibody to Agonize EPHB6 and DR5 for Triple-Negative Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CD19L-sTRAIL - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTB-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-8273 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dulanermin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Agonize TRAIL Receptor-2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GEN-1029 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HuG-4.2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HuGOH-729S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INBRX-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MEDI-3039 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Agonize DR5 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Agonize DR5 for Hematological Tumor and Solid Tumor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Agonize TRAILR2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NEO-214 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • POL-30000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCB-313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SL-231 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TLY-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Dormant Products
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Discontinued Products
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
  • Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
  • Sep 24, 2019: Theraly Fibrosis granted US Orphan Drug Designation for TLY012 for chronic pancreatitis
  • Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Peritoneal Carcinomatosis
  • Sep 03, 2019: Inhibrx reports phase 1 dose escalation results of INBRX-109, a multivalent agonist of death receptor 5
  • May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO
  • May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in China
  • Dec 06, 2018: Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
  • Dec 04, 2018: iDD biotech receives second milestone payment from Genmab with enrolment of fifth patient in Gen1029 safety trial
  • Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
  • Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition
  • Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbbVie Inc, H2 2019
  • Pipeline by Apollo Therapeutics LLC, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Beijing Sinotau Pharmaceutical Technology Co Ltd, H2 2019
  • Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
  • Pipeline by Biomirex Inc, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
  • Pipeline by Clover Biopharmaceuticals, H2 2019
  • Pipeline by D&D Pharmatech Co Ltd, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Galaxy Biotech LLC, H2 2019
  • Pipeline by Genmab A/S, H2 2019
  • Pipeline by i2 Pharmaceuticals Inc, H2 2019
  • Pipeline by IGM Biosciences Inc, H2 2019
  • Pipeline by Inhibrx Inc, H2 2019
  • Pipeline by JN Biosciences LLC, H2 2019
  • Pipeline by MacroGenics Inc, H2 2019
  • Pipeline by Neonc Technologies Inc, H2 2019
  • Pipeline by Obio Technology (Shanghai) Corp Ltd, H2 2019
  • Pipeline by Polaris Pharmaceuticals Inc, H2 2019
  • Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top